Open AccessRole of Postoperative Radiotherapy in Resected Non‐Small Cell Lung Cancer: A Reassessment Based on New Data
Author(s) -
Le Péchoux Cécile
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0150
Subject(s) - medicine , lung cancer , radiation therapy , oncology , chemotherapy , stage (stratigraphy) , randomized controlled trial , cancer , port (circuit theory) , mediastinal lymph node , disease , surgery , metastasis , paleontology , engineering , electrical engineering , biology
Learning Objectives After completing this course, the reader will be able to: Identify patients with non‐small cell lung cancer who may benefit from postoperative radiotherapy based upon current evidence. Summarize the results of analyses of both older and more recent data regarding postoperative radiotherapy in NSCLC patients.This article is available for continuing medical education credit at CME.TheOncologist.com In completely resected non‐small cell lung cancer (NSCLC) patients with pathologically involved mediastinal lymph nodes (N2), administration of adjuvant platinum‐based chemotherapy is now considered the standard of care, based on level 1 evidence. The role of postoperative radiation therapy (PORT) in this group of patients remains controversial. The PORT meta‐analysis published in 1998 concluded that adjuvant radiotherapy was detrimental to patients with early‐stage completely resected NSCLC, but that the role of PORT in the treatment of tumors with N2 involvement was unclear, and that further research was warranted. Recent retrospective and nonrandomized studies, as well as subgroup analyses of recent randomized trials evaluating adjuvant chemotherapy, provide evidence of the possible benefit of PORT in patients with mediastinal nodal involvement. The role of PORT is also a valid question in patients with proven N2 disease who have undergone only induction chemotherapy followed by surgery, because the local recurrence rate for such patients varies in the range of 20%–60%. Based on the currently available data, PORT should be discussed for fit patients with completely resected NSCLC with N2 nodal involvement, preferably after completion of adjuvant chemotherapy. There is a need for new randomized evidence to evaluate PORT using the modern three‐dimensional conformal radiation technique, with attention paid to reducing the risk for, particularly, pulmonary and cardiac toxicity. A new large multi‐institutional randomized trial evaluating PORT in this patient population is needed and now under way.